S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

Neurometrix Stock Price, Forecast & Analysis (NASDAQ:NURO)

$3.90
+0.36 (+10.17 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$3.21
Now: $3.90
$4.24
50-Day Range
$0.26
MA: $0.42
$3.62
52-Week Range
$2.52
Now: $3.90
$13.80
Volume461,800 shs
Average Volume17,540 shs
Market Capitalization$3.81 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NURO
CUSIPN/A
Phone781-890-9989

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.09 million
Cash Flow$0.35 per share
Book Value$0.79 per share

Profitability

Net Income$20,000.00

Miscellaneous

Employees42
Market Cap$3.81 million
Next Earnings Date1/23/2020 (Estimated)
OptionableNot Optionable

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.


Neurometrix (NASDAQ:NURO) Frequently Asked Questions

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Neurometrix shares reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

How were Neurometrix's earnings last quarter?

Neurometrix Inc (NASDAQ:NURO) announced its earnings results on Thursday, October, 17th. The medical device company reported ($0.14) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The medical device company earned $2.09 million during the quarter, compared to analyst estimates of $3.94 million. Neurometrix had a negative return on equity of 65.19% and a negative net margin of 48.86%. View Neurometrix's Earnings History.

When is Neurometrix's next earnings date?

Neurometrix is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for Neurometrix.

What price target have analysts set for NURO?

1 analysts have issued 1 year price targets for Neurometrix's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Neurometrix's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price. View Analyst Price Targets for Neurometrix.

What is the consensus analysts' recommendation for Neurometrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix.

Has Neurometrix been receiving favorable news coverage?

News articles about NURO stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurometrix earned a news impact score of 0.8 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Neurometrix.

Are investors shorting Neurometrix?

Neurometrix saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 142,300 shares, an increase of 20.5% from the September 30th total of 118,100 shares. Based on an average daily volume of 118,300 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.5% of the company's stock are sold short. View Neurometrix's Current Options Chain.

Who are some of Neurometrix's key competitors?

What other stocks do shareholders of Neurometrix own?

Who are Neurometrix's key executives?

Neurometrix's management team includes the folowing people:
  • Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
  • Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
  • Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
  • Mr. Michael J. MacDonald, Sr. VP of Commercial Operations & GM of Diagnostics
  • Dr. Xuan Kong Ph.D., Chief Data Scientist

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $3.90.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $3.81 million and generates $16.09 million in revenue each year. Neurometrix employs 42 workers across the globe.View Additional Information About Neurometrix.

What is Neurometrix's official website?

The official website for Neurometrix is http://www.neurometrix.com/.

How can I contact Neurometrix?

Neurometrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]


MarketBeat Community Rating for Neurometrix (NASDAQ NURO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Featured Article: G-20

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel